SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to improving the lives of transplant patients by a unique immunotherapeutic approach, today announced that interim results from the company’s MERCURY Phase 3 clinical trial will be presented by lead Principal Investigator Dr. Dixon Kaufman of the University of Wisconsin at the American Society of Nephrology (ASN) Kidney Week 2020, being held virtually from October 19-25, 2020. The presentation will review the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.
Details of the oral presentation are as follows:
Title: Interim Update of the MDR-101-MLK Phase 3 Trial – MERCURY STUDY
Session Number: Oral Abstract Session - 1901
Session Title: In-Depth Look at Transplantation: Basic and Translational
Date/ Time: Friday, October 23, 5:00pm-7:00pm ET
MDR-101 is intended to induce donor specific immune tolerance in order to avert transplant kidney rejection, eliminate the cumulative and serious side effects associated with immunosuppressive drugs and thereby preserve transplant kidney function and survival. Medeor’s Phase 3 trial is supported in part by a grant from the California Institute for Regenerative Medicine.
About Medeor Therapeutics, Inc.
Medeor Therapeutics is working to improve the lives of transplant patients by eliminating or reducing the need for a life-long regimen of immunosuppressant medications and their potential life-threatening side effects. Medeor’s Phase 3 clinical study is demonstrating the significant opportunities of this one-time therapy. For more information, visit www.medeortx.com.
